Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

BIMZELX - Health Canada Drug Approval Details

Approvals/Health Canada/BIMZELX

Authorized

STANDARD

BIMZELX

UCB Canada Inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 88ddb358914b71c8
Company: UCB Canada Inc
Type: Standard

Approval Details

Approval Id: 88ddb358914b71c8
Drug Approval Canada Name: BIMZELX
Product Name: BIMZELX
Status: Marketed
Status Date: 2025-04-07
Original Market Date: 2025-04-07
Din: 02553619
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 84:06.28
Atc Original: L04AC21 BIMEKIZUMAB
Atc Name: l 04 ac 21
Aig Number: 0163399001
Company Name: UCB Canada Inc
Company Address: 602, 2201 Bristol Circle, Oakville, Ontario, Canada, L6H 0J8

Active Ingredients

BIMEKIZUMAB

320 MG / 2 ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

88ddb358914b71c8

Type

Standard

Back to Health Canada Approvals